Impact of Pharmacist-Led Intervention on Adult Oncology Outpatients
ClinicalTrials.gov Studies
Summary
NCT07550478 is a registered clinical trial investigating pharmacist-led intervention (ST-CARE) among adult oncology outpatients managing polypharmacy. The study targets cancer patients receiving outpatient therapy who face elevated risk of medication discrepancies, drug-drug interactions, and nonadherence to oral anticancer therapies exceeding 40%. Pharmacists serve as the intervention arm, leveraging pharmacotherapy expertise to detect discrepancies, optimize medication use, and improve treatment adherence. The trial registration records study details on ClinicalTrials.gov with no stated compliance deadline for regulated entities.
“Pharmacists, as essential members of the multidisciplinary oncology team, are uniquely positioned to address these medication-related challenges.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NCT07550478 records a clinical trial on ClinicalTrials.gov evaluating a pharmacist-led intervention (ST-CARE) in adult oncology outpatients. The trial addresses medication discrepancies, drug-drug interactions, and adherence challenges among cancer patients receiving outpatient therapy, where nonadherence to oral anticancer therapies can exceed 40%. The pharmacist intervention arm leverages pharmacotherapy expertise and patient-education roles to optimize medication use. No compliance obligations, deadlines, or penalties are associated with this study registration — it is an informational record of planned research.
Healthcare providers and oncology programs should be aware that pharmacist integration into outpatient oncology care is an active area of clinical research. Institutions with oncology outpatient services may wish to monitor emerging evidence from trials such as this one, which may inform future clinical practice guidelines or quality-improvement initiatives.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Impact of Pharmacist-Led Intervention on Adult Oncology Outpatients
N/A NCT07550478 Kind: NA Apr 24, 2026
Abstract
Background and Rationale: Cancer patients receiving outpatient therapy often manage complex medication regimens that include anticancer agents, supportive care medications, and treatments for chronic comorbidities. This polypharmacy greatly increases the risk of medication discrepancies, potential drug-drug interactions, and unintentional errors. Moreover, because most oncology care is delivered in outpatient settings, patients are primarily responsible for self-administering their medications, making adherence a key determinant of treatment success and patient safety (Lindenmeyer et al., 2022; Alshehri et al., 2024). Medication errors and poor adherence among oncology patients are widely recognized global concerns. Research indicates that nearly half of cancer patients experience at least one medication discrepancy during transitions of care, and nonadherence to oral anticancer therapies can exceed 40%. Such issues can result in reduced treatment efficacy, increased toxicity, avoidable hospitalizations, higher healthcare costs, and poorer quality of life (Weingart et al., 2018; Wu et al., 2020; Patel et al., 2021). Pharmacists, as essential members of the multidisciplinary oncology team, are uniquely positioned to address these medication-related challenges. Their pharmacotherapy expertise and patient-education roles enable them to detect discrepancies, optimize medication use, and enhance patient understanding of treatment regimens. Evidence from various healthcare setti...
Conditions: Cancer
Interventions: Pharmacist intervention, ST- CARE
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.